Total Funding
73
64
Total FundingVenture - Series Unknown raised
Growth Score
0 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
46002
Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.
- David Main: President & CEOPast Role: Aquinox Pharmaceuticals, Chairman, President & CEO
- Shreya Shukla: Director, Research and Co-Founder
About the Company
Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible
processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells.
Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.
